Adjuvant therapy of colon cancer

Seminars in Oncology

Volumn 32, Issue 1 SPEC. ISS., 2005, Pages 95-102

  Sun, Weijing ^a   Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; BCG VACCINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOXICITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; META ANALYSIS; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; RISK REDUCTION; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 13844275193     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.037     Document Type: Article

References (67)

1. A. Jemal, T. Murray, A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5 26
2. American Joint Committee on Cancer AJCC Cancer Staging Manual ed 6 2002 Springer New York, NY 113 118
3. L.P. Fielding, P.A. Arsenault, P.H. Chapuis Working Report to the World Congress of Gastroenterology, Sydney 1990 J Gastroenterol Hepatol 6 1991 325 344
4. N.S. Goldstein, S. Weldon, M. Coffey Lymph node recovery from colorectal resection specimens removed for adenocarcinoma Trends over time and a recommendation for a minimum number of lymph nodes to be removed Am J Clin Pathol 106 1996 209 216
5. J.H. Wong, R. Serino, M.B. Hemmebier Number of nodes examined and staging accuracy in colorectal carcinoma J Clin Oncol 17 1999 2896 2900
6. T.E. Le Voyer, E.R. Sigurdson, A.L. Hanlon Colon cancer survival is associated with increasing number of lymph nodes analyzed A secondary survey of intergroup trial INT-0089 J Clin Oncol 21 2003 2912 2919
7. M.R. Griffin, E.J. Bergstralh, R.J. Coffey Predictors of survival after curative resection of carcinoma of the colon and rectum Cancer 60 1987 2318 2324
8. B.D. Minsky, C. Mies, T.A. Rich Potentially curative surgery of colon cancer. The influence of blood vessel invasion J Clin Oncol 6 1988 119 127
9. T. Wiggers, J.W. Arends, B. Schutte A multivariate analysis of pathologic prognostic indicators in large bowel cancer Cancer 61 1988 386 395
10. M.J. Krasna, L. Flancbaum, R.P. Cody Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance Cancer 61 1988 1018 1023
11. P. Peethambaram, M. Weiss, C.L. Loprinzi An evaluation of postoperative follow-up tests in colon cancer patients treated for cure Oncology 54 1997 287 292
12. O.A. Ogunbiyi, B.J. Goodfellow, K. Herfarth Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator J Clin Oncol 16 1998 427 433
13. M.-C. Etienne, M. Chazal, P. Laurent-Puig Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy Phenotypic and genotypic analysis J Clin Oncol 20 2002 2832 2843
14. C.J. Allegra, S. Paik Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study J Clin Oncol 21 2003 241 250
15. C.J. Allegra, A.L. Parr, L.E. Wold Investigation of the prognostic and predictive value of thymidylate synthetase, p53, and Ki-67 in patients with locally advanced colon cancer J Clin Oncol 20 2002 1735 1743
16. M. Buyse, A. Zeleniuch-Jaquotte, T. Chalmers Adjuvant therapy of colorectal cancer--Why we still don't know JAMA 259 1988 3571 3578
17. N. Wolmark, B. Fisher, L. Colangelo Postoperative adjuvant chemotherapy or BCG for colon cancer Results from NSABP protocol C-01 J Natl Cancer Inst 80 1988 30 36
18. H.S. Wieand, R. Smith, L. Colangelo Adjuvant therapy in carcinoma of the colon 10 year results of NSABP protocol C-01 Proc Am Soc Clin Oncol 20 2001 138a (abstr A550)
19. H. Verhaegen, J. DeCree, W. DeCock Levamisole therapy in patients with colorectal cancer W. Terry S. Rosenberg Immunotherapy of Human Cancer 1982 Elsevier New York, NY 225 229
20. J.A. Laurie, C.G. Moertel, T.R. Fleming The North Central Cancer Treatment Group and the Mayo Clinic Surgical adjuvant therapy of large bowel carcinoma An evaluation of levamisole and the combination of levamisole and 5-fluorouracil J Clin Oncol 7 1989 1447 1456
21. C.G. Moertel, T.R. Fleming, J.S. Macdonald Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322 1990 352 358
22. C.G. Moertel, T.R. Fleming, J.S. Macdonald Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma A final report Ann Intern Med 122 1995 321 326
23. National Institute of Health Consensus Conference Adjuvant therapy for patients with colon and rectal cancer JAMA 264 1990 1444 1450
24. Y.M. Rustum Modulation of fluoropyrimidines by leucovorin Rationale and status J Surg Oncol 2 suppl 1991 116 123
25. N. Wolmark, H. Rockette, B. Fisher The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03 J Clin Oncol 11 1993 1879 1887
26. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer Lancet 345 1995 939 944
27. D.G. Haller, P.J. Catalano, J.S. Macdonald Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer Preliminary results of INT-0089 Proc Am Soc Clin Oncol 15 1996 211 (abstr)
28. D.G. Haller, P.J. Catalano, J.S. Macdonald Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer Five-year final report of INT-0089 Proc Am Soc Clin Oncol 17 1998 265a (abstr 982)
29. N. Wolmark, H. Rockette, E. Mamounas Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon Results from the National Surgical Adjuvant Breast and Bowel Project C-04 J Clin Oncol 17 1999 3553 3559
30. B.G. Taal, H. Van Tinteren, F.A. Zoetmulder Adjuvant 5FU plus levamisole in colonic or rectal cancer Improved survival in stage II and III Br J Cancer 85 2001 1437 1443
31. H.T. Arkenau, A. Bermann, K. Rettig 5-Fluorouracil plus leucovorin is effective adjuvant chemotherapy in curatively resected stage III colon cancer Long-term follow-up results of the adjCCA-01 trial Ann Oncol 14 2003 395 399
32. L. Staib, K.H. Link, H.G. Beger Toxicity and effects of adjuvant therapy in colon cancer Result of the German prospective, control randomized multicenter trial FOGT-1 J Gastrointest Surg 5 2001 275 281
33. QUASAR Collaborative Group Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer A randomized trial Lancet 355 2000 1588 1596
34. T. Andre, P. Colin, C. Louvet Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer Results of a randomized trial J Clin Oncol 21 2003 2896 2903
35. A. Saini, A.R. Norman, D. Cunningham Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer Br J Cancer 88 2003 1859 1865
36. P.M. Hoff, R. Ansari, G. Bastist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer Results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
37. E. Van Cutsem, C. Twelves, J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer Results of a large phase III study J Clin Oncol 19 2001 4097 4106
38. W. Scheithauer, J. McKendrick, S. Begbie Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer Safety results of a randomized, phase III trial Ann Oncol 14 2003 1735 1743
39. J. Cassidy, W. Scheithauer, J. McKendrick Capecitabine (X) v bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study) Efficacy results of a phase III trial Proc Am Soc Clin Oncol 23 2004 A3509 (abstr)
40. M.L. Rothenberg, A.M. Oza, B. Burger Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin Proc Am Soc Clin Oncol 22 2003 a252 (abstr A1011)
41. R.M. Goldberg, R.F. Morton, D.J. Sargent N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study Proc Am Soc Clin Oncol 22 2003 a252 (abstr A1009)
42. L.B. Saltz, J.V. Cox, C.B. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
43. J.Y. Douillard, D. Cunningham, A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer A multicenter randomized trial Lancet 355 2000 1041 1047
44. M.L. Rothenberg, N.J. Meropol, E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin Summary finding of an independent panel J Clin Oncol 19 2001 3801 3807
45. D. Sargent, D. Niedzwiecki, M.J. O'Connell Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer N Engl J Med 345 2001 144 146
46. L.B. Saltz, D. Niedzwiecki, D. Hollis Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) Proc Am Soc Clin Oncol 23 2004 a246 (abstr A3500)
47. A. De Gramont, N. Vanzi, M. Navarro Oxaliplatin/5-FU/LV in adjuvant colon cancer Results of the international randomized mosaic trial Proc Am Soc Clin Oncol 22 2003 a253 (abstr 1015)
48. T. Andre, C. Boni, L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2344 2351
49. D.J. Sargent, S. Wieand, J. Benedetti Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies Individual patient data from 12,915 patients on 15 randomized trials Proc Am Soc Clin Oncol 23 2004 A3502 (abstr)
50. G. Riethmuller, E. Holz, G. Schlimok Monoclonal antibody therapy for rectal Dukes' C colorectal carcinoma Seven year outcome of a multicenter randomized trial J Clin Oncol 16 1998 1788 1794
51. C.J. Punt, A. Nagy, J.Y. Douillard Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer A randomised study Lancet 360 2002 671 677
52. A.L. Fields, A.M. Keller, L. Schwartzberg Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer Results of a randomized North American phase III study Proc Am Soc Clin Oncol 21 2002 128a (abstr A508)
53. D.G. Haller Update of clinical trials with edrecolomab A monoclonal antibody therapy for colorectal cancer Semin Oncol 28 suppl 1 2001 25 30
54. E. Mamounas, S. Wieand, N. Wolmark Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol 17 1999 1349 1355
55. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer J Clin Oncol 17 1999 1356 1363
56. S. Marsoni IMPACT investigators Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer Semin Oncol 28 suppl 1 2001 14 19
57. C.G. Moertel, T.R. Fleming, J.S. Macdonald Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer J Clin Oncol 13 1995 2936 2943
58. th International Conference on Colorectal Cancer in Paris Semin Oncol 28 suppl 1 2001 1 3
59. A.B. Benson III, D. Schrag, M.R. Somerfield American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 23 2004 3408 3419
60. R.G. Gray, B.R. Hills, R. Hills QUASAR A randomized study of adjuvant chemotherapy (CT) v observation including 3238 colorectal cancer patients Proc Am Soc Clin Oncol 23 2004 A3501 (abstr)
61. T. Hikish, C. Boni, M. Navarro FOLFOX4 as adjuvant treatment for stage II colon cancer (CC) Subpopulation data from the MOSAIC trial Proc Am Soc Clin Oncol 23 2004 A3619 (abstr)
62. D.J. Sargent, R.M. Goldberg, S.D. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 2001 1091 1097
63. T.J. Iwashyna, E.B. Lamont Effectiveness of adjuvant fluorouracil in clinical practice A population-based cohort study of elderly patients with stage III colon cancer J Clin Oncol 20 2002 3992 3998
64. D. Schrag, S. Gelfand, P. Bach Adjuvant chemotherapy for stage II colon cancer Insight from a SEER-Medicare cohort Proc Am Soc Clin Oncol 20 2001 123a (abstr 488)
65. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
66. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
67. http://www.nci.nih.gov/clinicaltrials/developments/newly-approved- treatments/page11